EMA hesitates over flunking Curevac vaccine despite missed target

The European Medicines Agency is reluctant to implement the 50 percent efficacy threshold for covid-19 vaccines.

Photo: Yves Herman/REUTERS / X00380

On Thursday, the European Medicines Agency (EMA) reported that it will not be implementing a 50 percent efficacy threshold for covid-19 vaccines.

On Wednesday, it emerged that the Curevac vaccine has 47 percent efficacy. It therefore does not live up to statistical success criteria.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs